IBA, Elekta ink proton therapy center partnership

Lisa Fratt | | Health Imaging | Oncology Imaging
Elekta will integrate cancer workflow and patient management tools into the Proteus TK2, a proton therapy center from Belgium-based Ion Beam Applications (IBA).

The IBA proton therapy system includes a cyclotron, beam line, gantry treatment room and a fixed-beam treatment room.

Stockholm-based Elekta software and devices included in the Proteus TK2 center are the MOSAIQ oncology information system; auto-segmentation tools which provide treatment planning functionality that supports conventional radiation and proton beam therapies; non-invasive patient immobilization and positioning systems and respiratory motion management.

Lisa Fratt

Related Content

Imaging may be misleading when determining the success of cancer treatment
Prostate cancer radiotherapy timeline can be safely shortened
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection
VI-RADS threshold, imaging features predict bladder cancer invasiveness with nearly 100% accuracy
PHOTO GALLERY: thyroid nodule imaging

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.